Exploratory Study to Investigate the Reparative and Regenerative Potential of Alemtuzumab in Relapsing-Remitting Multiple Sclerosis Patients Participating in the CARE MS I and MS II Studies

This study has been completed.
Sponsor:
Information provided by:
Wayne State University
ClinicalTrials.gov Identifier:
NCT01020370
First received: November 24, 2009
Last updated: NA
Last verified: November 2009
History: No changes posted

November 24, 2009
November 24, 2009
Not Provided
Not Provided
Explore the reparative and regenerative potential of alemtuzumab in RRMS patients who are participating in the CARE MS I and CARE MS II studies
Same as current
No Changes Posted
Compare the effect of alemtuzumab to interferon beta-1a SC on non-conventional MRI outcomes
Same as current
Not Provided
Not Provided
 
Exploratory Study to Investigate the Reparative and Regenerative Potential of Alemtuzumab in Relapsing-Remitting Multiple Sclerosis Patients Participating in the CARE MS I and MS II Studies
An Exploratory Study to Investigate the Reparative and Regenerative Potential of Alemtuzumab in Relapsing-Remitting Multiple Sclerosis: A Multi-Parametric Non-Conventional MRI Sub-Study in Patient Participating in the CARE MS I and CARE MS II Studies

The primary goal of this study will be to explore the reparative and regenerative potential of alemtuzumab in RRMS patients who are participating in the CARE MS I and CARE MS II studies using conventional and non-conventional MRI sequences.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Patients with RRMS who are participating in the CARE MS I and CARE MS II studies and are receiving either alemtuzumab or interferon beta-1a SC

Multiple Sclerosis
Not Provided
  • Alemtuzumab Group
  • Interferon Beta-1a SC Group
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
Not Provided
Not Provided

Inclusion Criteria:

  • Participating in either the CARE MS I or CARE MS II studies

Exclusion Criteria:

  • Not a participant in the CARE MS I or CARE MS II studies
Both
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT01020370
CAMMS030081ST
Not Provided
Not Provided
Wayne State University
Not Provided
Principal Investigator: Omar Khan, MD Wayne State University
Wayne State University
November 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP